Table 2.
The therapeutic effect, donor chimerism analysis, and acute GVHD after anti-CD19-CAR T-cell therapy.
| Patient | Donor Type | CR/Cri | MRD | Donor chimerism (%) | Time of aGVHD (Days after CAR-T therapy) | Grade of aGVHD | Site of aGVHD | Therapy to aGVHD |
|---|---|---|---|---|---|---|---|---|
| Pt 1# | MMUDT (8/10) | Cri | Negative | 99.86 | 60–102 | II | S2, G1 | Glucocorticoid, CsA |
| Pt 2# | MSDT | CR | Negative | 99.83 | 35–97 | I | S2 | Glucocorticoid |
| Pt 3# | Haplo-HSCT (7/10) | CR | Negative | 99.92 | 32–77 | II | G1 | Glucocorticoid |
| Pt 4# | Haplo-HSCT (5/10) | Cri | Negative | 99.86 | 52–64 | III | L3 | Glucocorticoid, CsA, Anti-CD25 monoclonal antibody |
| Pt 5# | Haplo-HSCT (5/10) | Cri | Negative | 99.91 | 24–104 | IV | S3, L2, G4 | Glucocorticoid, CsA, Ruxolitinib |
| Pt 6# | MUDT | NR | Positive | 10.72 | 0 | 0 | - | - |
| Pt 7# | Haplo-HSCT (5/10) | CR | Negative | 99.94 | 0 | 0 | - | - |
| Pt 8# | MSDT | CR | Positive | 99.94 | 51–93 | I | S1 | Glucocorticoid |
| Pt 9# | Haplo-HSCT (5/10) | CR | Negative | 99.94 | 0 | 0 | - | - |
| Pt 10# | MSDT | Cri | Positive | 99.77 | 0 | 0 | - | - |
| Pt 11# | MSDT | CR | Negative | 99.66 | 42–74 | I | S1 | Glucocorticoid |
| Pt 12# | Haplo-HSCT (5/10) | Cri | Negative | 99.91 | 0 | 0 | - | - |
| Pt 13# | Haplo-HSCT (5/10) | NR | Positive | 99.56 | 31–102 | III | S3, G3 | Glucocorticoid, CsA, Ruxolitinib |
| Pt 14# | Haplo-HSCT (5/10) | Cri | Negative | 99.86 | 21–73 | IV | S4, L2, G4 | Glucocorticoid, CsA, Ruxolitinib |
| Pt 15# | Haplo-HSCT (5/10) | Cri | Negative | 99.17 | 14–56 | I | S1 | Glucocorticoid |
S, Skin; L, Liver, G, Gastrointestinal.